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Glycogen is a macromolecule (103–104 kDa); a polymer of
glucosyl units present in a substantial amount in the brain
relative to free glucose (Glc) (Gruetter 2003; Watanabe and
Passonneau 1973). Interestingly, in the adult brain, glycogen
is found only in astrocytes. Although under normal physio-
logy it seems that this store is metabolized actively but
comparatively slowly (Oz et al. 2007), glycogen support of
astrocyte metabolism (Dienel and Cruz 2004), neuronal
metabolism (Gibbs et al. 2006; Suh et al. 2007), or both
could be important in prolonging neuronal activity (Brown
et al. 2005) and limiting neuronal death. We have previously
shown that the brain can store more than a few minutes’
supply of Glc equivalent as glycogen (Morgenthaler et al.
2006). Therefore, glial glycogen may act as a substantial
source of Glc equivalents during acute insulin-induced
hypoglycemia (Choi et al. 2003; Gruetter 2003; Morgent-
haler et al. 2006) or during hypoxia-ischemia (Allen et al.
2005; Gruetter 2003; Nordstrom and Siesjo 1978; Rossi
et al. 2007). Recently, it has been suggested that glycogen
might be involved in learning in young chickens (Gibbs
et al. 2006, 2008a, 2007). Glycogen may also be neuro-
protective (Swanson and Choi 1993). One possible neuro-
protective mechanism of glial glycogen might be to provide
lactate as fuel for neurons (Magistretti and Pellerin 1996) and
to provide ATP to allow continuous uptake of excitotoxic
glutamate from the synaptic cleft (Gruetter 2003). However,
such neuroprotection might interfere with proper recognition
of hypoglycemia by interfering with Glc-sensing neurons.
Therefore, it has also been suggested that brain glycogen
might be implicated in the mechanism of hypoglycemia
unawareness syndrome observed clinically in patients with
type I diabetes (Choi et al. 2003; Cryer 2005, 2006; Gruetter
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Abstract
The only currently available method to measure brain
glycogen in vivo is 13C NMR spectroscopy. Incorporation of
13C-labeled glucose (Glc) is necessary to allow glycogen
measurement, but might be affected by turnover changes. Our
aim was to measure glycogen absolute concentration in the
rat brain by eliminating label turnover as variable. The ap-
proach is based on establishing an increased, constant 13C
isotopic enrichment (IE). 13C-Glc infusion is then performed at
the IE of brain glycogen. As glycogen IE cannot be assessed
in vivo, we validated that it can be inferred from that of
N-acetyl-aspartate IE in vivo: After [1-13C]-Glc ingestion,
glycogen IE was 2.2 ± 0.1 fold that of N-acetyl-aspartate
(n = 11, R2 = 0.77). After subsequent Glc infusion, glycogen
IE equaled brain Glc IE (n = 6, paired t-test, p = 0.37),
implying isotopic steady-state achievement and complete
turnover of the glycogen molecule. Glycogen concentration
measured in vivo by 13C NMR (mean ± SD: 5.8 ± 0.7 lmol/g)
was in excellent agreement with that in vitro (6.4 ± 0.6 lmol/
g, n = 5). When insulin was administered, the stability of
glycogen concentration was analogous to previous biochem-
ical measurements implying that glycogen turnover is
activated by insulin. We conclude that the entire glycogen
molecule is turned over and that insulin activates glycogen
turnover.
Keywords: 13C, insulin, nuclear magnetic resonance, turn-
over.
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2003). Hypoglycemia unawareness is a very dangerous state
characterized by the lack of warning symptoms of hypo-
glycemia prior to cognitive dysfunction, and rapid progres-
sion to severe hypoglycemia with confusion and coma.
There is normally an ongoing simultaneous utilization
and resynthesis of brain glycogen with an active turnover
resulting in consistent levels of brain glycogen under resting
conditions (Brown and Ransom 2007; Choi et al. 2003;
Watanabe and Passonneau 1973). Interestingly, glycogen
turnover is increased during activation of brain tissue
(Dienel et al. 2007; Dienel and Cruz 2003, 2004; Shulman
et al. 2001; Swanson 1992). Moreover, extracellular Glc
concentration (Brown et al. 2003; Morgenthaler et al.
2006), as well as numerous neurotransmitters (Sorg and
Magistretti 1992) have been reported to inﬂuence glycogen
content in the brain. For example, insulin increases brain
glycogen metabolism (Choi et al. 2003; Morgenthaler et al.
2006).
13C Nuclear Magnetic Resonance (NMR) is the only
currently available method capable of measuring brain
glycogen non-invasively. As 13C natural abundance is low,
13C NMR studies rely on measuring the incorporation of
13C-labeled Glc into the glycogen molecule to enhance the
signal. Therefore, the observed increase in 13C signal over
time might not necessarily be reﬂecting changes in concen-
tration alone, but also an increased incorporation of the 13C
label. We have previously shown that changes in glycogen
concentration measured by 13C NMR were in excellent
agreements with biochemical measurements (Lei et al. 2007;
Morgenthaler et al. 2006). However, the increase in glycogen
concentration after insulin infusion was smaller when studied
with biochemical methods (Morgenthaler et al. 2006) as
compared to in vivo 13C NMR studies (Choi et al. 2003).
This difference might be because of an effect of insulin on
glycogen turnover.
The aim of this study was to develop a new approach that
allows the measurement of in vivo brain glycogen absolute
concentration. The pre-requisite consisted of minimizing the
inﬂuence of turnover – a potential confounding factor – in
the 13C NMR measurement of glycogen. The strategy was to
pre-label the rat and achieve a near steady-state Isotopic
Enrichment (IE) using long term [1-13C]-Glc administration.
Glycogen IE was measured in vivo and this IE was matched
by the subsequent 13C-labeled Glc infusion, thus maintaining
isotopic steady-state throughout the experiment. Conse-
quently, the effects of insulin on brain glycogen concentra-
tion could be directly studied.
Materials and methods
‘Rationale’
In vivo 13C Nuclear Magnetic Resonance (NMR) spectroscopy of
glycogen is based on observing the incorporation of 13C label into
glycogen (Choi and Gruetter 2003; Choi et al. 2003, 1999; Gruetter
et al. 2003; Karelson et al. 2003; Oz et al. 2003). Therefore an
increase in 13C signal over time is not necessarily reﬂecting an
increase in glycogen absolute concentration [as illustrated in the
scheme of Fig. 1a(i–iii)].
The major aim of this study was to measure glycogen absolute
concentration and second to eliminate label turnover (exchange with
the glycogen molecule) as a potential confounding factor. Our
approach is based on ‘pre-labeling’ rat brain glycogen by long-term
[1-13C]-labeled Glc administration until steady-state of 13C enrich-
ment (i.e. constant over time) was reached. Infusion of [1-13C]-
labeled Glc then continues with the same Isotopic Enrichment (IE,
see eqn 1) as brain glycogen (isotopic steady-state) [Fig. 1b(i)].
IE ¼
13C
13C þ 12Cð Þ ð1Þ
Subsequently, observed changes in glycogen signal intensity only
reﬂect changes in absolute concentration and not label turnover into
the glycogen molecule [Fig. 1b(i–iii)].
The approach depends on continuing the infusion at the IE of
glycogen. As brain glycogen IE cannot be assessed in vivo, we
investigated its indirect estimation through measuring N-acetyl-
aspartate (NAA) IE, which can be directly measured in vivo. NAA
was chosen because of the excellent correlation between the amount
of labeled Glc incorporated into brain glycogen and into NAA
previously described; as well as the similar turnover time of these
two molecules (Choi and Gruetter 2003). Therefore, once the
isotopic steady-state is reached, the IE of glycogen should be
mimicked by that of NAA.
Together with the known brain glycogen IE, the reliable
quantiﬁcation of 13C-labeled glycogen implies that brain glycogen
absolute concentration can be calculated by dividing the glycogen
13C NMR signal by glycogen IE.
Rat ‘pre-labeling’
Rats were fasted overnight with free access to water before studies
were performed. The following day they received a 10% w/v
[1-13C]-labeled Glc solution (99% [1-13C]-enriched) ad libitum as
their sole source of exogeneous carbon for 24 h (n = 11) or 48 h
(n = 6). Most of the rats labeled for 24 h received a 99% 13C-
enriched solution (n = 9), but rats pre-labeled during 48 h received a
50% 13C-enriched solution as labeling solution, to optimize the cost
of the experiment.
To keep the ratio between glycogen IE and NAA IE stable and
allow the calculation of glycogen IE from NAA IE, rats were pre-
labeled in a quiet and familiar environment as glycogen turnover has
been reported to be increased during brain activation (Dienel et al.
2007; Dienel and Cruz 2003, 2004; Shulman et al. 2001; Swanson
1992).
Animal preparation
The study was performed in accordance with the local and federal
guidelines and was approved by the local ethics committee.
Two main groups of rats were studied. The ﬁrst group (n = 11,
mean weight ± SD: 240 ± 27 g, Sprague–Dawley rats, Harlan,
Madison, WI, USA) was used for validation of the method for
indirect estimation of glycogen IE via NAA IE measurement. The
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rats were pre-labeled for either 24 h (n = 5) or 48 h (n = 6). They
were anesthetized using isoﬂurane (isoﬂurane, Halocarbon labora-
tories, 5% for induction and 1.8–2.0% for maintenance) in a 70 : 35
mixture of nitrous oxide (N2O) and oxygen (O2) gases for
preparation. Then, rats were intubated and ventilated with a
pressure-driven ventilator (Kent Scientiﬁc, Litchﬁeld, CT, USA)
for the rest of the experiment. They were placed into the 9.4 T
magnet and their body temperature was maintained at 37.5 ± 0.5C
with circulating heated water (RTE-101 bath circulator, Thermo
NESLAB, Portsmouth, NH, USA). In vivo measurement of NAA IE
was performed. The animal was then killed and in vitro measure-
ments (NAA IE for validation, glycogen concentration and glycogen
IE) were performed on the brain extracts (see below).
With the second group of rats (n = 6), brain glycogen absolute
concentration was measured in vivo (see below), as well as the
effects on brain glycogen of insulin infusion over time. Glycogen IE
was calculated at the beginning of the experiment from the in vivo
measurement of NAA IE. Male Sprague–Dawley rats (mean
weight ± SD: n = 6, 247 ± 38 g, Charles River, France) were pre-
labeled during 24 h and prepared as described above and previously
(Morgenthaler et al. 2006). Respiratory rate and pattern were
monitored during experiments with a respiratory pillow (SA
Instruments, Stony Brook, NY, USA). Preparation consisted of
inserting catheters into both femoral arteries for blood gases and Glc
analysis, and into both femoral veins for i.v. infusion of a-chloralose
(97%, Acros Organics, Geel, Belgium), [1-13C]-Glc (Cambridge
Isotope Laboratories Inc., Andover, MA, USA) mixed with D-Glc
(Sigma, St Louis, MO, USA), and insulin (Humulin R, Eli Lilly and
Company, Indianapolis, IN, USA).
Immediately after preparation, anesthesia was switched to
a-chloralose, which was administered i.v. as follows: 15 min after
a 80 mg/kg bolus injection, a continuous i.v. infusion was started
(26.7 mg/kg/h) to maintain a light anesthesia state according to
previous report (Ueki et al. 1992). All solutions used for i.v.
infusion were diluted in Dulbecco’s Phosphate-Buffered Saline
(without calcium chloride and without magnesium chloride, Sigma).
Arterial blood was withdrawn from the femoral artery through a
polyethylene tubing line (PE50, Becton-Dickinson, Franklin Lakes,
NJ, USA) roughly every 30 min. Around 0.05 mL of blood was used
to measure physiological parameters with a pH/blood gas analyzer
(AVL Compact 3 BGA, Roche Diagnostics, Rotkreuz, Switzerland)
while the rest of the blood (0.15 mL) was immediately centrifuged
to obtain plasma. Plasma Glc concentration was measured using the
Glc oxidase method in a Glc analyzer (GM7 Micro-stat, Analox
Instruments, London, UK). Physiologic parameters (respiration rate
and breathing volume) were adjusted throughout the experiments to
maintain pCO2 and pH within normal physiological ranges (mean
pH ± SD = 7.31 ± 0.04; mean pCO2 ± SD = 43.5 ± 1.8 and mean
body temperature ± SD = 38.1 ± 0.2) (Morgenthaler et al. 2006).
The infusion rate of Glc (20% weight/volume in Dulbecco’s
Phosphate-Buffered Saline) was continuously adjusted based on the
measured plasma Glc concentrations to maintain target glycemia.
The IE of the infusate was calculated from the in vivo measurement
of NAA IE at the beginning of each experiment (see below). Glc
(ai) (aii) (aiii)
(bi) (bii) (biii)
Fig. 1 Schematic illustration of the effect of label turnover on glycogen
quantification. (a) Brain glycogen is labeled by infusing a highly
enriched solution of 13C-labeled Glc (dark spheres) into an unlabeled
rat (a-i) femoral vein. Light spheres represent 12C-Glc (so-called
unlabeled Glc). An increase in 13C signal can be observed over time
(represented by an increase in the number of dark spheres), even in
the absence of changes in brain glycogen concentration (the total
number of spheres does not change over time). The 13C signal
augmentation is thus because of an increase in glycogen IE over time.
(b) The new method uses long term administration of 13C-labeled Glc
prior to the measurement to achieve significant brain glycogen IE.
After measuring this IE in vivo (using NAA IE as an indirect method),
the same IE of the infused Glc solution is matched to that of brain
glycogen IE and the 13C-NMR glycogen measurement is started. By
subsequently infusing a Glc solution whose IE is similar to that of
glycogen, glycogen IE remains stable over time and therefore no
change in signal intensity is observed unless the absolute glycogen
concentration changes (total number of spheres). Due to glycogen
turnover, represented by the arrow, the glycogen concentration in the
rat brain remains constant (schematized here as a constant number of
spheres) despite the infusion of glucose. N.B.: 13C natural abundance
(1.1%) has been neglected (especially in a-i).
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infusion rate was adjusted to maintain plasma Glc levels during
insulin infusion (Morgenthaler et al. 2006).
In vivo magnetic resonance spectroscopy
In vivo magnetic resonance spectroscopy experiments were
performed on an actively shielded 9.4 T/31 cm magnet (Magnex
Scientiﬁc, Abingdon, Oxon, UK) with actively shielded gradients
(400 mT/m in 120 ms, 12 cm inner diameter) connected to a
Varian INOVA console (Varian, Palo, Alto, CA, USA). A
quadrature 14 mm 1H coil combined with a three-turn linearly
polarized 13C coil 10 mm diameter was used for radio frequency
transmission and signal reception. A sphere containing 99% 13C-
enriched formic acid (FA) was located at the center of the 13C
coil as an external reference, and the coil was placed on the
animal’s head as described previously (Choi et al. 2001, 2000,
1999; Lei et al. 2007). FASTMAP (Gruetter and Tkac 2000) was
applied in 100–150 lL volumes of interest to adjust magnetic
ﬁeld inhomogeneity. A Single-shot Inversion Recovery based
Non-Echo sequence with optimized outer volume suppression
(Choi et al. 2000) was applied for 3D localization (inversion time
for glycogen was 0.12 s) to ensure elimination of signals from
non-cerebral tissue (Choi et al. 2001, 2000, 1999; Lei et al.
2007). Bilevel WALTZ-16 RF pulses were applied at the 1H
water frequency to generate a nuclear Overhauser effect and to
decouple during acquisition (Choi et al. 2000; Lei et al. 2007).
The robustness of localization was veriﬁed from the absence of
the natural abundance lipid signal (30.5 ppm) in spectra opti-
mized for the amino acid region by placing the carrier frequency
at 30.5 ppm and thus minimizing the chemical shift displacement
error (20–40 ppm) as lipid signals are not detectable in the
normal brain in vivo (Choi and Gruetter 2003).
In vivo NAA IE measurement using 1H NMR
N-acetyl-aspartate IE was measured by 1H NMR using a localized
ACED-STEAM sequence (Pfeuffer et al. 1999a). 256 scans
(repetition time = 4 s; echo time TE = 7.9 ms; mixing time
TM = 25 ms) were acquired in 17 min. In the 13C-edited 1H
spectrum, only 1H bound to 13C in different metabolites were thus
observed. The two interleaved recorded spectra were apodized by 5-
Hz exponential line broadening, zero-ﬁlled and Fourier transformed.
They were then subtracted and yielded the 1H-13C resonances and
edited for JCH = 129 Hz. The non-edited
1H spectrum (Fig. 2a,
upper spectrum) enabled the measurement of the [6-12C]-NAA 1H
signal at 2.01 ppm (Pfeuffer et al. 1999b), while the 13C-edited 1H
spectrum (Fig. 2a, lower spectrum) allowed to measure the doublet
of the labeled [6-13C]-NAA molecule. As the downﬁeld satellite at
2.17 ppm [6-13C]-NAA 1H signal was slightly overlapped by
glutamate, only the 1.85 ppm [6-13C]-NAA 1H signal was used for
measurement. NAA IE was thus obtained by dividing twice the
intensity of the 1.85 ppm [6-13C]-NAA 1H signal, by twice the
intensity of the 1.85 ppm [6-13C]-NAA 1H signal plus the [6-12C]-
NAA 1H signal intensity.
In vivo brain glycogen concentration measurement using 13C NMR
Glycogen and Glc signals were acquired in 34 min (2048 scans,
repetition time = 1 s) using the Single-shot Inversion Recovery
based Non-Echo sequence. They were summed, apodized by 25-Hz
exponential line broadening, zero-ﬁlled, and Fourier transformed.
Fig. 2 Comparison of in vivo measurement of NAA Isotopic Enrich-
ment (IE) with in vitro measurement. (a) Example of in vivo NAA
spectra with and without editing. It can be observed that the 2.17 ppm
13C peak satellite is slightly larger because of glutamate contamina-
tion. (b) Example of in vitro spectrum. Signals are much better sepa-
rated. *NAA-G. (c) In vivo measurement of [6-13C]-NAA IE is identical
to in vitro measurement (n = 9 rats, paired t-test, p = 0.62). The result
of linear regression is shown.
 2008 The Authors
Journal Compilation  2008 International Society for Neurochemistry, J. Neurochem. (2008) 107, 1414–1423
Brain glycogen absolute concentration in vivo | 1417
Two blocks of spectra were acquired before insulin infusion (as
baseline) and seven blocks after insulin infusion.
The glycogen C1 signal intensity was ﬁtted by a Gaussian line
shape with a ﬁxed linewidth using the spectrometer software (Varian
Inc.). The linewidth was obtained from the ﬁt to a spectrum
summing all acquisitions. Quantiﬁcation was performed using the
external reference method (Gruetter et al. 1991; Lei et al. 2007),
based on the measurement of the signal from a phantom containing
500 mM of natural abundance oyster glycogen (Sigma). Phantom
measurements were performed under identical experimental condi-
tions (temperature, number of scans, position in the magnet,
localized volume) to the in vivo studies.
In vivo 13C absolute glycogen concentration [Glyc]invivo was
calculated by comparing the in vivo NMR signal I invivoglyc with the
phantom signal Iphanglyc while taking the known phantom concentration
[Glyc]phan and in vivo IE of glycogen IEGlyc into account as in
previous studies (Choi et al. 1999; Lei et al. 2007). A correction for
the difference in coil loading was made by multiplying by the ratio
of the formic acid reference signal (IFA) in both cases, and by an
experimentally determined correction factor (a = 0.98) for the
slightly different magnetic relaxation behavior of rat and oyster
glycogen under a short T1 and nuclear Overhauser effect. The ﬁnal
equation was:
Glyc½ invivo¼
I invivoglyc
Iphanglyc
 I
phan
FA
IinvivoFA
 1:1%
IEglyc
 a Glyc½ phan ð2Þ
Natural abundance in the oyster phantom solution was assumed
to be 1.1% and [Glyc]phan was 500 mM.
Tissue analysis
At the end of each experiment, rats were killed using a focused
microwave ﬁxation device by applying 4 kW onto a 2 mL volume
for 1.4–1.6 s (Gerling Applied Engineering, Inc., Modesto, CA,
USA) which inactivates most brain enzymes before extraction or
digestion, thereby minimizing possible in vitro glycogen loss (Kong
et al. 2002). The anterior parts of the brain (excluding cerebellum)
were dissected, and immediately placed into liquid nitrogen and
manually reduced to powder with a pestle and mortar. Brain powder
was stored at )80C until further processing.
Glycogen assay
Biochemical measurement of brain glycogen was performed on
brain extracts as previously described (Cruz and Dienel 2002;
Morgenthaler et al. 2006). Brieﬂy, 0.03 M HCl (500 lL) was
carefully added to frozen brain powders (200 mg) in tubes on dry
ice. Brain powders were homogenized (ultrasonic processor, Cole-
Parmer Instruments, Vernon Hills, IL, USA), heated to 90C for
45 min and homogenized again. For the glycogen assay, sodium
acetate (Sigma) was added to 200 lL samples in 0.03 M HCl. Well-
mixed portions of each sample were incubated at 37C for at least
2 h with gentle mixing in a water bath (Julabo SW 22, Milian,
Gahanna, OH, USA) in two parallel aliquots, one containing amylo-
a-1,4-a-1,6-glucosidase (24 lg/mL, Roche) to convert glycogen to
Glc and the other without amylo-a-1,4-a-1,6-glucosidase (this latter
sample allowed brain Glc concentration as well as IE measure-
ments). Glc levels were determined using the same Analox
instrument as above. Glycogen levels per gram wet weight were
calculated as Glc released by amylo-a-1,4-a-1,6-glucosidase, that is,
Glc level after incubation with amyloglucosidase minus that without
the enzyme (Ghajar et al. 1982).
In vitro 1H-NMR: Glc IE, glycogen IE and NAA IE measurement
13C IE (see eqn 1) of NAA, Glc and digested glycogen were further
determined in vitro by 1H NMR, using a Bruker Avance-DRX 600
(14.1 T, 600 MHz) spectrometer (Bruker BioSpin SA, Fa¨llanden,
Switzerland). Samples obtained from the glycogen assay were
ﬁltered (Ultrafree-CL ﬁlters, Millipore Corporation, Bedford, MA,
USA) to remove high molecular weight molecules. They were
lyophilized in a speedVac (DNA 120, SpeedVac Concentrator,
Thermo electron corporation) and resuspended into 500 lL D2O
(deuterium oxide, 99.9 atom % D, Aldrich, Germany).
For [1-13C]-Glc IE measurement, 1H spectra were acquired at
44C using a delay time of 15 s. The 1H NMR spectra were
calibrated with H2O (HDO) ﬁxed at 4.6 ppm upﬁeld to tetramethyl-
silane (internal standard for NMR calibration). The level of
[1-13C]-Glc was determined by appropriate integration of the 1H
signals (bound to Glc C1) of the a-anomer. 1H signals consisted of a
doublet for the unlabeled molecule (chemical shift: 5.28 ppm,
3JH1,H2 = 3.7 Hz) and a doublet of doublets for the C1-labeled
molecule [the 1JC1,H1 coupling (170 Hz) superimposed on the
smaller 3JH1,H2 coupling (3.7 Hz)].
In vitro the IE of Glc was calculated from applying eqn 1 to the
integrals obtained from the in vitro spectrum. Brain Glc IE was
directly measured with the high resolution 600 MHz magnet. Brain
glycogen IE was calculated according to eqn 3 after having
processed the brain extracts with the glycogen assay so that the
glycogen molecule was digested into Glc molecular units (Lei et al.
2007).
IEglyc ¼ IETotalGlc  TotalGlc½ ð Þ  IEBrainGlc  BrainGlc½ ð ÞGlyc½  ð3Þ
Total Glc (TotalGlc) represents brain Glc (BrainGlc) plus
digested brain glycogen, i.e. measurement performed in samples
subjected to amyloglucosidase digestion. Total Glc and brain Glc IE
were obtained by high ﬁeld 1H-spectroscopy, and brain Glc and
glycogen concentrations were obtained by biochemical measure-
ment.
After having measured brain Glc and ‘total Glc’ IE, the pH of the
samples was lowered to 1.8 with 0.1 M DCl. 1H NMR spectra were
acquired at 25C with a repetition time of 9 s. They were calibrated
with H2O (HDO) ﬁxed at 4.8 ppm upﬁeld to tetramethylsilane. The
level of [6-13C]-NAA IE was determined by appropriate integration
(see above) of the 1H signals bound to NAA C6. 1H signals
consisted of a single peak for the unlabeled molecule (chemical
shift: 2.01 ppm) and a doublet for the C6-labeled molecule
(1JC1,H1 coupling: 129 Hz). In vitro NAA IE was calculated from
eqn 1 (Fig. 2b).
Results
During the ‘pre-labeling period’, the rats ingested signiﬁcant
amounts of [1-13C]-labeled Glc solution either for 24 h
[mean Glc solution (10% w/v) ingested ± SD: 122 ± 27 mL,
n = 11] or for 48 h (170 ± 68 mL, n = 6).
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With the ﬁrst group of rats (n = 11), our pre-labeling
method was validated as follows: There was no signiﬁcant
difference between NAA IE measured in vivo and subse-
quently in vitro in the same brains (Fig. 2c, n = 9, paired
t-test, p = 0.62) conﬁrming the validity of the in vivo
measurement of NAA IE. NAA IE was correlated (n = 11,
R2 = 0.82) with the amount of [1-13C]-Glc ingested by each
rat (Fig. 3) and no signiﬁcant difference could be observed
between 24 or 48 h of pre-labeling. There was also less
variability in the amount of 13C-labeled Glc solution ingested
by the rats after 24 h than after 48 h. We therefore decided to
pre-label the rats only during 24 h for the rest of the
experiments. The biochemical measurements of glycogen
concentration in the post-mortem brain extracts yielded
4.5 ± 1.0 lmol/g (mean ± SD). Finally, the in vitro mea-
surement of glycogen IE allowed us to measure the
relationship between glycogen IE and NAA IE; glycogen
IE was 2.2 ± 0.1 times that of NAA IE (mean ± SD, n = 11,
Fig. 4b) as expected from the breakdown of [1-13C]-Glc into
two molecules of acetyl-CoA. Taken together these results
(see Figs 2c and 4b in particular) showed that brain glycogen
IE can be inferred from the in vivo measurement of NAA IE
after 24 h of pre-labeling.
With the second group of rats (n = 6), we measured brain
glycogen absolute concentration in vivo after 24 h of pre-
labeling (Fig. 5). From the NAA IE (mean percentage ± SD:
15.3 ± 2.3%, n = 6), the IE of the Glc infusion solution was
adjusted to 36 ± 6% based on the 2.2-fold difference in IE
(see above). Nine blocks of glycogen spectra were then
acquired. The ﬁrst two blocks were taken as reference.
Insulin infusion (24 IU/kg) was then started and plasma Glc
was maintained at 10 mM (mean plasma Glc ± SD:
10.7 ± 0.5 mM, n = 6) by adjusting the infusion rate of the
Glc solution. The brain 13C-glycogen signal (Fig. 5b) was
typically detected with a high signal to noise ratio on the
order of 8 : 1. Absolute glycogen concentration obtained
in vivo (mean ± SD: 5.8 ± 0.7 lmol/g, n = 6) by 13C NMR
was in excellent agreement with biochemical determination
(mean ± SD: 6.4 ± 0.6 lmol/g, n = 5, paired t-test, p = 0.12,
Fig. 5c). At the end of 7 h of Glc infusion, brain Glc IE was
similar to the IE of the infused Glc solution (n = 6, paired
t-test, p = 0.52, data not shown) and glycogen IE (n = 6,
paired t-test, p = 0.37, Fig. 6).
Finally, the effects of insulin infusion on brain glycogen
concentration were investigated in vivo and over time. The
infusion of insulin together with Glc over 4.5 h did not
signiﬁcantly affect brain glycogen concentration measured
by in vivo NMR (n = 5 rats, paired t-test between the last
measurement before insulin infusion and the last measure-
ment during insulin infusion, p = 0.5) (Fig. 7).
Discussion
We show for the ﬁrst time that the non-invasive measure-
ment of brain glycogen concentration is feasible. This is
possible by accurate quantiﬁcation of the labeled propor-
tion of the glycogen molecule and therefore of the total
Fig. 4 At isotopic near steady-state enrichment, NAA IE reflects gly-
cogen IE. (a) Example of in vitro Glc 1H resonance of the a-anomer at
5.28 ppm used for calculating brain Glc and glycogen IE. (b) In vitro
measurement of 13C-glycogen IE as a function of [6-13C]-NAA IE after
[1-13C]-Glc ingestion (n = 11). Shown is the result of linear regression.
Fig. 3 NAA IE is correlated with the amount of [1-13C]-Glc ingested by
the rat. [6-13C]-NAA IE as a function of the amount of [1-13C]-Glc
ingested (in grams) by the rat (n = 11). Shown is the result of linear
regression.
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brain glycogen content. Matching the IE of the Glc
infusate solution to the IE of glycogen allowed us to
perform time-resolved measurement of brain glycogen
concentration.
The in vivo brain glycogen concentration obtained by 13C
NMR spectroscopy in the present study was similar to
subsequent biochemical measurement in the same brain and
to previous biochemical measurements of brain glycogen
concentration (mean ± SD: 6.2 ± 0.6 lmol/g). Furthermore,
the in vitro measurements of brain glycogen concentration of
the ﬁrst group of rats were in perfect agreement with
previous measurement made in rats after short isoﬂurane
anesthesia (Morgenthaler et al. 2006). As expected, the pre-
labeling protocol did not alter brain glycogen concentration,
which is consistent with Glc being sufﬁcient for brain
metabolism under these conditions.
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Fig. 5 In vivo measurement of brain glycogen absolute concentration.
(a) Scheme summarizing the experimental protocol for ‘time course
experiments’. (b) Example of in vivo 13C NMR spectrum showing
localized detection of [1-13C]-glycogen and [1-13C]-Glc (a and b ano-
mers). (c) No significant difference between glycogen absolute con-
centration measured in vivo by NMR spectroscopy (last measurement
before kill) and in vitro in the post-mortem brain extracts (n = 5 rats,
paired t-test, p = 0.12). Error bars indicate SD.
Fig. 6 Glycogen turnover is complete. At the end of the time course
experiment, brain glycogen isotopic enrichment was similar to the
isotopic enrichment of brain Glc (n = 6 rats). Shown is the result of
linear regression.
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That brain Glc IE was similar to the IE of the Glc infusate
at the end of the time course experiments was expected from
the rapid equilibration of plasma Glc across the blood brain
barrier (Choi et al. 2001; Gruetter et al. 1998). Moreover, the
stability of the IE of glycogen over 7 h of Glc infusion
equaling that of brain Glc suggests near complete turnover of
the glycogen molecule after a 24 h pre-labeling period. As a
consequence, glycogen turnover is unlikely to be a con-
founding effect after 24 h of pre-labeling. Since 24 h of pre-
labeling seem sufﬁcient to nearly reach isotopic steady-state,
we conclude that the slower turnover time of limit dextrin
(Watanabe and Passonneau 1973) is sufﬁciently fast to lead
to near-complete turnover in 24 h. As the pre-labeling period
of 24 h is longer than glycogen (Choi et al. 1999; Oz et al.
2007; Watanabe and Passonneau 1973) and NAA (Choi and
Gruetter 2003) turnover times, the IE of both of these
molecules should be close to steady-state. In other words,
both turnover curves are expected to evolve in a similar
manner.
N-acetyl-aspartate was chosen as a ‘reporter molecule’ to
estimate glycogen IE for two main reasons. First, NAA has a
similar turnover time to glycogen (Choi and Gruetter 2003)
and second NAA is synthesized early in the Glc metabolic
pathway, just after glycolysis. The ratio close to 2 : 1
between glycogen IE and NAA IE observed here suggests
that Glc is the major source of NAA biosynthesis.
The effect of insulin on brain glycogen metabolism
measured previously by 13C NMR suggested a several fold
increase in glycogen concentration or metabolism (Choi
et al. 2003). However, when measured with biochemical
methods (Morgenthaler et al. 2006) the increase in glycogen
concentration after insulin infusion was less than 1 lmol/g
over 4.5–5 h of insulin (6 units/kg/h) infusion. The present
study did not show a signiﬁcant increase of brain glycogen
concentration over time, however, the average SEM of
0.5 lmol/g corresponding to a 95% conﬁdence interval of
about ± 1 lmol/g allows for such small increases. These
results suggest that insulin has a modest effect on glycogen
concentration (around 1.0 lmol/g over 4.5 h). Therefore, the
present study is within experimental error in very good
agreement with the previous biochemical determination of
glycogen concentration (Morgenthaler et al. 2006) rather
than the previous 13C NMR measurements with rats that had
not been pre-labeled (Choi et al. 2003). Together with the
previous NMR observation of several-fold increased 13C
incorporation into glycogen (Choi et al. 2003), the apparent
stability of the glycogen signal in the current study implies
that insulin mainly increases glycogen turnover rather than
glycogen concentration. The modest effect of insulin on
glycogen concentration and the more pronounced effect on
turnover are consistent with insulin crossing the blood brain
barrier (Banks 2004) and affecting insulin sensitive pathways
such as glycogen metabolism.
We have previously shown that acute hypoglycemia
promoted glycogenolysis at an enhanced rate (Choi et al.
2003, 1999). This increased glycogenolysis was not com-
pensated by enhanced glycogen synthesis as it resulted in
net reduction of glycogen concentration (Morgenthaler
et al. 2006). Previous studies have reported changes in
glycogen concentration during physiological activation
(Cruz and Dienel 2002; Dienel et al. 2007; Swanson et al.
1992), which were performed at euglycemia and in awake
animals, unlike the present study. It is quite possible that
insulin acts on glycogen by a different mechanism than
activation, likely mediated in the latter case by noradren-
ergic mechanisms (Gibbs et al. 2008b; Sorg and Magistretti
1991).
We conclude that pre-labeling a rat with [1-13C]-labeled
Glc for 24 h is adequate to obtain nearly total turnover of the
glycogen molecule, to measure glycogen absolute concen-
(a)
(b)
Fig. 7 Apparent stability of the time-resolved NMR signal of glycogen
during insulin infusion. (a) Time resolved stack plot (one spectrum
each 34 min) of in vivo 13C spectra acquired in one rat showing
localized detection of [1-13C]-glycogen and [1-13C]-Glc (a and b ano-
mers). Whereas [1-13C]-Glc infusion was performed during the whole
experiment (to maintain plasma glycemic levels around 10 mM) at an
IE matching that estimated for glycogen, insulin infusion was started
after the acquisition of the first two spectra (shown in grey). (b) Mean
brain glycogen concentration (n = 5 rats) over time. n = 5 out of the six
rats of this group; absolute quantification of glycogen was not possible
in one rat because of instrument failure. The arrow indicates when
insulin infusion started. Error bars indicate SEM.
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tration, and to monitor glycogen concentration changes over
time. Moreover, this protocol shows that insulin activates
brain glycogen synthesis and breakdown simultaneously.
We further conclude that brain glycogen absolute concen-
tration can be measured in vivo in a time-resolved manner,
which should allow important insight into the role of
glycogen in glial cells.
Acknowledgements
We wish to thank Arthur Magill for his careful reading of the
manuscript. This work was supported by the ‘Centre d’Imagerie
Biome´dicale’ (CIBM) of the University of Lausanne (UNIL), the
Federal Institute of Technology in Lausanne (EPFL), the University
of Geneva (UniGe), the ‘Centre Hospitalier Universitaire Vaudois’
(CHUV) and the ‘Hoˆpitaux Universitaires Genevois’ (HUG); and by
the Leenards and the Jeantet Foundations; and by NIH grant
R01NS042005.
References
Allen N. J., Karadottir R. and Attwell D. (2005) A preferential role for
glycolysis in preventing the anoxic depolarization of rat hippo-
campal area CA1 pyramidal cells. J. Neurosci. 25, 848–859.
Banks W. A. (2004) The source of cerebral insulin. Eur. J. Pharmacol.
490, 5–12.
Brown A. M. and Ransom B. R. (2007) Astrocyte glycogen and brain
energy metabolism. Glia 55, 1263–1271.
Brown A. M., Tekkok S. B. and Ransom B. R. (2003) Glycogen regu-
lation and functional role in mouse white matter. J. Physiol. 549,
501–512.
Brown A. M., Sickmann H. M., Fosgerau K., Lund T. M., Schousboe A.,
Waagepetersen H. S. and Ransom B. R. (2005) Astrocyte glycogen
metabolism is required for neural activity during aglycemia or
intense stimulation in mouse white matter. J. Neurosci. Res. 79,
74–80.
Choi I. Y. and Gruetter R. (2003) In vivo 13C NMR assessment of brain
glycogen concentration and turnover in the awake rat. Neurochem.
Int. 43, 317–322.
Choi I. Y., Tkac I., Ugurbil K. and Gruetter R. (1999) Noninvasive
measurements of [1-(13)C]glycogen concentrations and meta-
bolism in rat brain in vivo. J. Neurochem. 73, 1300–1308.
Choi I. Y., Tkac I. and Gruetter R. (2000) Single-shot, three-dimensional
‘‘non-echo’’ localization method for in vivo NMR spectroscopy.
Magn. Reson. Med. 44, 387–394.
Choi I. Y., Lee S. P., Kim S. G. and Gruetter R. (2001) In vivo mea-
surements of brain glucose transport using the reversible Micha-
elis-Menten model and simultaneous measurements of cerebral
blood ﬂow changes during hypoglycemia. J. Cereb. Blood Flow
Metab. 21, 653–663.
Choi I. Y., Seaquist E. R. and Gruetter R. (2003) Effect of hypoglycemia
on brain glycogen metabolism in vivo. J. Neurosci. Res. 72, 25–32.
Cruz N. F. and Dienel G. A. (2002) High glycogen levels in brains of rats
with minimal environmental stimuli: implications for metabolic
contributions of working astrocytes. J. Cereb. Blood Flow Metab.
22, 1476–1489.
Cryer P. E. (2005) Mechanisms of hypoglycemia-associated autonomic
failure and its component syndromes in diabetes. Diabetes 54,
3592–3601.
Cryer P. E. (2006) Hypoglycemia in diabetes: pathophysiological
mechanisms and diurnal variation. Prog. Brain Res. 153, 361–365.
Dienel G. A. and Cruz N. F. (2003) Neighborly interactions of metaboli-
cally-activated astrocytes in vivo. Neurochem. Int. 43, 339–354.
Dienel G. A. and Cruz N. F. (2004) Nutrition during brain activation:
does cell-to-cell lactate shuttling contribute signiﬁcantly to sweet
and sour food for thought? Neurochem. Int. 45, 321–351.
Dienel G. A., Ball K. K. and Cruz N. F. (2007) A glycogen phosphorylase
inhibitor selectively enhances local rates of glucose utilization in
brain during sensory stimulation of conscious rats: implications for
glycogen turnover. J. Neurochem. 102 (2), 466–478.
Ghajar J. B., Plum F. and Duffy T. E. (1982) Cerebral oxidative
metabolism and blood ﬂow during acute hypoglycemia and
recovery in unanesthetized rats. J. Neurochem. 38, 397–409.
Gibbs M. E., Anderson D. G. and Hertz L. (2006) Inhibition of glyco-
genolysis in astrocytes interrupts memory consolidation in young
chickens. Glia 54, 214–222.
Gibbs M. E., Lloyd H. G., Santa T. and Hertz L. (2007) Glycogen is a
preferred glutamate precursor during learning in 1-day-old chick:
biochemical and behavioral evidence. J. Neurosci. Res. 85, 3326–
3333.
Gibbs M. E., Bowser D. N., Hutchinson D. S., Loiacono R. E. and
Summers R. J. (2008a) Memory processing in the avian hippo-
campus involves interactions between beta-adrenoceptors, gluta-
mate receptors, and metabolism. Neuropsychopharmacology 33
(12), 2831–2846.
Gibbs M. E., Hutchinson D. and Hertz L. (2008b) Astrocytic involve-
ment in learning and memory consolidation. Neurosci. Biobehav.
Rev. 32 (5), 927–944.
Gruetter R. (2003) Glycogen: the forgotten cerebral energy store.
J. Neurosci. Res. 74, 179–183.
Gruetter R. and Tkac I. (2000) Field mapping without reference scan
using asymmetric echo-planar techniques. Magn. Reson. Med. 43,
319–323.
Gruetter R., Prolla T. A. and Shulman R. G. (1991) 13C NMR visibility
of rabbit muscle glycogen in vivo. Magn. Reson. Med. 20, 327–
332.
Gruetter R., Ugurbil K. and Seaquist E. R. (1998) Steady-state cerebral
glucose concentrations and transport in the human brain. J. Neu-
rochem. 70, 397–408.
Gruetter R., Adriany G., Choi I. Y., Henry P. G., Lei H. and Oz G. (2003)
Localized in vivo 13C NMR spectroscopy of the brain. NMR
Biomed. 16, 313–338.
Karelson G., Ziegler A., Kunnecke B. and Seelig J. (2003) Feeding
versus infusion: a novel approach to study the NAA metabolism in
rat brain. NMR Biomed. 16, 413–423.
Kong J., Shepel P. N., Holden C. P., Mackiewicz M., Pack A. I. and
Geiger J. D. (2002) Brain glycogen decreases with increased
periods of wakefulness: implications for homeostatic drive to sleep.
J. Neurosci. 22, 5581–5587.
Lei H., Morgenthaler F., Yue T. and Gruetter R. (2007) Direct validation
of in vivo localized 13C MRS measurements of brain glycogen.
Magn. Reson. Med. 57, 243–248.
Magistretti P. J. and Pellerin L. (1996) Cellular bases of brain energy
metabolism and their relevance to functional brain imaging: evi-
dence for a prominent role of astrocytes. Cereb. Cortex 6, 50–61.
Morgenthaler F. D., Koski D. M., Kraftsik R., Henry P. G. and Gruetter
R. (2006) Biochemical quantiﬁcation of total brain glycogen con-
centration in rats under different glycemic states. Neurochem. Int.
48, 616–622.
Nordstrom C. H. and Siesjo B. K. (1978) Effects of phenobarbital in
cerebral ischemia. Part I: cerebral energy metabolism during pro-
nounced incomplete ischemia. Stroke 9, 327–335.
Oz G., Henry P. G., Seaquist E. R. and Gruetter R. (2003) Direct,
noninvasive measurement of brain glycogen metabolism in
humans. Neurochem. Int. 43, 323–329.
Journal Compilation  2008 International Society for Neurochemistry, J. Neurochem. (2008) 107, 1414–1423
 2008 The Authors
1422 | F. D. Morgenthaler et al.
Oz G., Seaquist E. R., Kumar A., Criego A. B., Benedict L. E., Rao J. P.,
Henry P. G., Van De Moortele P. F. and Gruetter R. (2007) Human
brain glycogen content and metabolism: implications on its role in
brain energy metabolism. Am. J. Physiol. Endocrinol. Metab. 292,
E946–E951.
Pfeuffer J., Tkac I., Choi I. Y., Merkle H., Ugurbil K., Garwood M. and
Gruetter R. (1999a) Localized in vivo 1H NMR detection of
neurotransmitter labeling in rat brain during infusion of [1-13C]
D-glucose. Magn. Reson. Med. 41, 1077–1083.
Pfeuffer J., Tkac I., Provencher S. W. and Gruetter R. (1999b) Toward an
in vivo neurochemical proﬁle: quantiﬁcation of 18 metabolites in
short-echo-time (1)H NMR spectra of the rat brain. J. Magn.
Reson. 141, 104–120.
Rossi D. J., Brady J. D. and Mohr C. (2007) Astrocyte metabolism and
signaling during brain ischemia. Nat. Neurosci. 10, 1377–1386.
Shulman R. G., Hyder F. and Rothman D. L. (2001) Cerebral energetics
and the glycogen shunt: neurochemical basis of functional imag-
ing. Proc. Natl Acad. Sci. USA 98, 6417–6422.
Sorg O. and Magistretti P. J. (1991) Characterization of the glycogeno-
lysis elicited by vasoactive intestinal peptide, noradrenaline and
adenosine in primary cultures of mouse cerebral cortical astrocytes.
Brain Res. 563, 227–233.
Sorg O. and Magistretti P. J. (1992) Vasoactive intestinal peptide and
noradrenaline exert long-term control on glycogen levels in
astrocytes: blockade by protein synthesis inhibition. J. Neurosci.
12, 4923–4931.
Suh S.W., Bergher J. P., Anderson C.M., Treadway J. L., Fosgerau K. and
Swanson R. A. (2007) Astrocyte glycogen sustains neuronal activity
during hypoglycemia: studies with the glycogen phosphorylase
inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(meth-
oxymethylamino)-3-oxo-1-(phenylmet hyl)propyl]-1H-indole-2-
carboxamide). J. Pharmacol. Exp. Ther. 321, 45–50.
Swanson R. A. (1992) Physiologic coupling of glial glycogen metabo-
lism to neuronal activity in brain. Can. J. Physiol. Pharmacol.
70(Suppl), S138–S144.
Swanson R. A. and Choi D. W. (1993) Glial glycogen stores affect
neuronal survival during glucose deprivation in vitro. J. Cereb.
Blood Flow Metab. 13, 162–169.
Swanson R. A., Morton M. M., Sagar S. M. and Sharp F. R. (1992)
Sensory stimulation induces local cerebral glycogenolysis: dem-
onstration by autoradiography. Neuroscience 51, 451–461.
Ueki M., Mies G. and Hossmann K. A. (1992) Effect of alpha-chloral-
ose, halothane, pentobarbital and nitrous oxide anesthesia on
metabolic coupling in somatosensory cortex of rat. Acta Anaes-
thesiol. Scand. 36, 318–322.
Watanabe H. and Passonneau J. V. (1973) Factors affecting the turnover
of cerebral glycogen and limit dextrin in vivo. J. Neurochem. 20,
1543–1554.
 2008 The Authors
Journal Compilation  2008 International Society for Neurochemistry, J. Neurochem. (2008) 107, 1414–1423
Brain glycogen absolute concentration in vivo | 1423
